China Resources Pharmaceutical Group Limited (CR Pharma; 03320) reported unaudited first-quarter 2026 results for its consolidated subsidiary Dong-E-E-Jiao.

Financial highlights for the three months ended 31 March 2026 (PRC GAAP, unaudited):

• Revenue reached RMB 1.81 billion, up 5.5% from RMB 1.72 billion in the prior-year period.

• Net profit rose 7.1% year on year to RMB 454.77 million.

• Net cash inflow from operating and investing activities expanded to RMB 1.22 billion, markedly higher than RMB 390.67 million a year earlier.

• Cash and cash equivalents closed the quarter at RMB 4.62 billion, versus RMB 3.12 billion at the end of Q1 2025.

Balance-sheet snapshot (as at 31 March 2026):

• Total assets stood at RMB 13.55 billion, up 1.3% from 31 December 2025.

• Total liabilities fell 10.1% to RMB 2.71 billion, lowering the liability-to-asset ratio to roughly 20.0%.

• Owner’s equity increased to RMB 10.84 billion from RMB 10.36 billion at 2025 year-end.

Ownership structure:

CR Pharma holds a 10.19% direct stake in Dong-E-E-Jiao and controls a further 13.31% through its non-wholly-owned subsidiary, China Resources Dong-E-E-Jiao Company Limited, giving the Group an effective interest of approximately 23.50%.

The figures are unaudited and may be adjusted during the annual audit process. Investors are advised to consult the full quarterly filing on the Shenzhen Stock Exchange website for comprehensive details.